Historical Valuation
Quince Therapeutics Inc (QNCX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.64. The fair price of Quince Therapeutics Inc (QNCX) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：2.69
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Quince Therapeutics Inc (QNCX) has a current Price-to-Book (P/B) ratio of 154.38. Compared to its 3-year average P/B ratio of 12.86 , the current P/B ratio is approximately 1100.41% higher. Relative to its 5-year average P/B ratio of 9.74, the current P/B ratio is about 1485.42% higher. Quince Therapeutics Inc (QNCX) has a Forward Free Cash Flow (FCF) yield of approximately -23.33%. Compared to its 3-year average FCF yield of -57.53%, the current FCF yield is approximately -59.44% lower. Relative to its 5-year average FCF yield of -55.03% , the current FCF yield is about -57.60% lower.
P/B
Median3y
12.86
Median5y
9.74
FCF Yield
Median3y
-57.53
Median5y
-55.03
Competitors Valuation Multiple
AI Analysis for QNCX
The average P/S ratio for QNCX competitors is 78.92, providing a benchmark for relative valuation. Quince Therapeutics Inc Corp (QNCX.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for QNCX
1Y
3Y
5Y
Market capitalization of QNCX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of QNCX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is QNCX currently overvalued or undervalued?
Quince Therapeutics Inc (QNCX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.64. The fair price of Quince Therapeutics Inc (QNCX) is between to according to relative valuation methord.
What is Quince Therapeutics Inc (QNCX) fair value?
QNCX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Quince Therapeutics Inc (QNCX) is between to according to relative valuation methord.
How does QNCX's valuation metrics compare to the industry average?
The average P/S ratio for QNCX's competitors is 78.92, providing a benchmark for relative valuation. Quince Therapeutics Inc Corp (QNCX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Quince Therapeutics Inc (QNCX) as of Jan 10 2026?
As of Jan 10 2026, Quince Therapeutics Inc (QNCX) has a P/B ratio of 154.38. This indicates that the market values QNCX at 154.38 times its book value.
What is the current FCF Yield for Quince Therapeutics Inc (QNCX) as of Jan 10 2026?
As of Jan 10 2026, Quince Therapeutics Inc (QNCX) has a FCF Yield of -23.33%. This means that for every dollar of Quince Therapeutics Inc’s market capitalization, the company generates -23.33 cents in free cash flow.
What is the current Forward P/E ratio for Quince Therapeutics Inc (QNCX) as of Jan 10 2026?
As of Jan 10 2026, Quince Therapeutics Inc (QNCX) has a Forward P/E ratio of -4.01. This means the market is willing to pay $-4.01 for every dollar of Quince Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Quince Therapeutics Inc (QNCX) as of Jan 10 2026?
As of Jan 10 2026, Quince Therapeutics Inc (QNCX) has a Forward P/S ratio of 0.00. This means the market is valuing QNCX at $0.00 for every dollar of expected revenue over the next 12 months.